Davis SL et al. The development of regorafenib and its current and potential future role in cancer therapy. Drugs Today (Barc) 2013;49(2):105-15. Abstract

Mross K et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 2012;18(9):2658-67. Abstract

Shahda S, Saif MW. Regorafenib: From bench to bedside in colorectal cancer. Expert Rev Clin Pharmacol 2013;6(3):243-8. Abstract

Strumberg D et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: A phase I study. Br J Cancer 2012;106(11):1722-7. Abstract

Van Cutsem E et al. Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial. Proc ASCO 2013;Abstract 3636.